- Company
- Biosimilar Ultomiris to follow Soliris next year at earliest
- by Kim, Jin-Gu Nov 4, 2019 03:12pm
- Sources predict Ultomiris would enter the Korean market and a competition against a blockbuster antibody, Soliris, next year. According to pharmaceutical industry on Oct. 30, the drug manufacturer of Ultomiris, Alexion is preparing for a launch in Korea at the end of next year. The follow-on antibody drug already has been approved by
- Company
- Companies ready litigation against valsartan damage claim
- by Chon, Seung-Hyun Nov 4, 2019 03:10pm
- The second deadline for valsartan damage indemnity payment the health authority is claiming from pharmaceutical companies has been passed. Most of companies are refusing to pay and preparing for litigation. 34 companies have decided to take a joint legal action and designated a large law firm to represent them. According to an industry insid
- Company
- Pfizer's 50 years of ‘changes and innovation’ in Korea
- by Byun Kyung A Nov 4, 2019 08:13am
- Half a century in Korean pharmaceutical industry, Pfizer Korea seems to have mastered ‘how to win’ in the Korean market. Pfizer took its first step into the Korean market as a joint corporation with Joongang Pharmaceutical in 1962 and founded Pfizer Korea in 1969. Except for a couple of times, Pfizer Korea since then consistently rec
